trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase

Virology

Volumn 388, Issue 1, 2009, Pages 57-67

  Heipertz Jr , Richard A ^a   Starkey, Jason L ^a   Miller, Thomas G ^a   Hu, Jianming ^a   Isom, Harriet C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Baculovirus; Drug resistant; HBV; Polymerase; Reverse transcriptase; rtM204I; trans Complementation; Viral interaction

Indexed keywords

GENOMIC RNA; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; BACULOVIRUS; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE;

CELL LINE; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; MUTATION;

HEPATITIS B VIRUS;

EID: 67349154958     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.03.018     Document Type: Article

References (56)

1. Abdelhamed A.M., Kelley C.M., Miller T.G., Furman P.A., Cable E.E., and Isom H.C. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob. Agents. Chemother. 47 1 (2003) 324-336
2. Allen M.I., Deslauriers M., Andrews C.W., Tipples G.A., Walters K.A., Tyrrell D.L., Brown N., and Condreay L.D. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 6 (1998) 1670-1677
3. Bartenschlager R., Junker-Niepmann M., and Schaller H. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J. Virol. 64 11 (1990) 5324-5332
4. Bartholomew M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Bunzendahl H., Condreay L.D., Tzakis A.G., Schiff E.R., and Brown N.A. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349 9044 (1997) 20-22
5. Blum H.E., Galun E., Liang T.J., von Weizsacker F., and Wands J.R. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J. Virol. 65 4 (1991) 1836-1842
6. Bouchard M.J., and Schneider R.J. The enigmatic X gene of hepatitis B virus. J. Virol. 78 23 (2004) 12725-12734
7. Cane P.A., Mutimer D., Ratcliffe D., Cook P., Beards G., Elias E., and Pillay D. Analysis of hepatitis B virus quasispecies changes during emergence and reversion of lamivudine resistance in liver transplantation. Antivir. Ther. 4 1 (1999) 7-14
8. Chang T.T., Lai C.L., Chien R.N., Guan R., Lim S.G., Lee C.M., Ng K.Y., Nicholls G.J., Dent J.C., and Leung N.W. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 19 11 (2004) 1276-1282
9. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., Lok A.S., Han K.H., Goodman Z., Zhu J., Cross A., DeHertogh D., Wilber R., Colonno R., and Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354 10 (2006) 1001-1010
10. Chayama K., Suzuki Y., Kobayashi M., Kobayashi M., Tsubota A., Hashimoto M., Miyano Y., Koike H., Kobayashi M., Koida I., Arase Y., Saitoh S., Murashima N., Ikeda K., and Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 6 (1998) 1711-1716
11. Chiang P.W., Hu C.P., Su T.S., Lo S.C., Chu M.H., Schaller H., and Chang C.M. Encapsidation of truncated human hepatitis B virus genomes through trans-complementation of the core protein and polymerase. Virology 176 2 (1990) 355-361
12. de Man R.A., Honkoop P., Janssen H.L., and Schalm S.W. Chronic hepatitis-b-virus infections: new options for antiviral therapy. Ned. Tijdschr. Geneeskd. 143 37 (1999) 1857-1861
13. Delaney IV W.E., and Isom H.C. Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus. Hepatology 28 4 (1998) 1134-1146
14. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., Crowther L., Condreay L.D., Woessner M., Rubin M., and Brown N.A. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341 17 (1999) 1256-1263
15. Fu L., and Cheng Y.C. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. Biochem. Pharmacol. 55 10 (1998) 1567-1572
16. Gaillard R.K., Barnard J., Lopez V., Hodges P., Bourne E., Johnson L., Allen M.I., Condreay P., Miller W.H., and Condreay L.D. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob. Agents. Chemother. 46 4 (2002) 1005-1013
17. Gao W., and Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J. Virol. 81 12 (2007) 6164-6174
18. Girones R., and Miller R.H. Mutation rate of the hepadnavirus genome. Virology 170 2 (1989) 595-597
19. Heipertz Jr. R.A., Miller T.G., Kelley C.M., Delaney IV W.E., Locarnini S.A., and Isom H.C. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J. Virol. 81 7 (2007) 3068-3076
20. Hirsch R.C., Lavine J.E., Chang L.J., Varmus H.E., and Ganem D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 344 6266 (1990) 552-555
21. Hirsch R.C., Loeb D.D., Pollack J.R., and Ganem D. cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J. Virol. 65 6 (1991) 3309-3316
22. Honkoop P., Niesters H.G., de Man R.A., Osterhaus A.D., and Schalm S.W. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26 6 (1997) 1393-1395
23. Hu J., Flores D., Toft D., Wang X., and Nguyen D. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J. Virol. 78 23 (2004) 13122-13131
24. Jarvis B., and Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58 1 (1999) 101-141
25. Junker-Niepmann M., Bartenschlager R., and Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 9 10 (1990) 3389-3396
26. Kagawa T., Watanabe N., Kanouda H., Takayama I., Shiba T., Kanai T., Kawazoe K., Takashimizu S., Kumaki N., Shimamura K., Matsuzaki S., and Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J. Gastroenterol. 10 11 (2004) 1686-1687
27. Kim J.W., Lee H.S., Woo G.H., Yoon J.H., Jang J.J., Chi J.G., and Kim C.Y. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin. Infect. Dis. 33 3 (2001) 403-405
28. Knaus T., and Nassal M. The encapsidation signal on the hepatitis B virus RNA pregenome forms a stem-loop structure that is critical for its function. Nucleic Acids Res. 21 17 (1993) 3967-3975
29. Knowles B.B., Howe C.C., and Aden D.P. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209 4455 (1980) 497-499
30. Lai C.L., Dienstag J., Schiff E., Leung N.W., Atkins M., Hunt C., Brown N., Woessner M., Boehme R., and Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36 6 (2003) 687-696
31. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., Chen Y., Heathcote E.J., Rasenack J., Bzowej N., Naoumov N.V., Di Bisceglie A.M., Zeuzem S., Moon Y.M., Goodman Z., Chao G., Constance B.F., and Brown N.A. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357 25 (2007) 2576-2588
32. Lanford R.E., Notvall L., Lee H., and Beames B. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71 4 (1997) 2996-3004
33. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., Chung Y.H., Lee Y.S., Yoo W., and Kim S.O. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 6 (2006) 1385-1391
34. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 2 (1999) 567-572
35. Litwin S., Toll E., Jilbert A.R., and Mason W.S. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J. Clin. Virol. 34 Suppl. 1 (2005) S96-S107
36. Mauss S., and Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert. Rev. Anti. Infect. Ther. 6 2 (2008) 191-199
37. Melegari M., Scaglioni P.P., and Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27 2 (1998) 628-633
38. Nguyen D.H., and Hu J. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 82 14 (2008) 6852-6861
39. Okamoto H., Wang Y., Tanaka T., Machida A., Miyakawa Y., and Mayumi M. Trans-complementation among naturally occurring deletion mutants of hepatitis B virus and integrated viral DNA for the production of viral particles with mutant genomes in hepatoma cell lines. J. Gen. Virol. 74 Pt 3 (1993) 407-414
40. Ono-Nita S.K., Kato N., Shiratori Y., Masaki T., Lan K.H., Carrilho F.J., and Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29 3 (1999) 939-945
41. Pallier C., Castera L., Soulier A., Hezode C., Nordmann P., Dhumeaux D., and Pawlotsky J.M. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 80 2 (2006) 643-653
42. Peters M.G., Singer G., Howard T., Jacobsmeyer S., Xiong X., Gibbs C.S., Lamy P., and Murray A. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68 12 (1999) 1912-1914
43. Pollack J.R., and Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol. 67 6 (1993) 3254-3263
44. Pollack J.R., and Ganem D. Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J. Virol. 68 9 (1994) 5579-5587
45. Radziwill G., Tucker W., and Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J. Virol. 64 2 (1990) 613-620
46. Santantonio T., Mazzola M., Iacovazzi T., Miglietta A., Guastadisegni A., and Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32 2 (2000) 300-306
47. Starkey J.L., Chiari E.F., and Isom H.C. Hepatitis B virus (HBV)-specific short hairpin RNA is capable of reducing the formation of HBV covalently closed circular (CCC) DNA but has no effect on established CCC DNA in vitro. J. Gen. Virol. 90 Pt 1 (2009) 115-126
48. Suzuki Y., Yotsuyanagi H., Okuse C., Nagase Y., Takahashi H., Moriya K., Suzuki M., Koike K., Iino S., and Itoh F. Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report. World J. Gastroenterol. 13 6 (2007) 964-969
49. Tavis J.E., and Ganem D. Evidence for activation of the hepatitis B virus polymerase by binding of its RNA template. J. Virol. 70 9 (1996) 5741-5750
50. Tavis J.E., Massey B., and Gong Y. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J. Virol. 72 7 (1998) 5789-5796
51. Wang G.H., Zoulim F., Leber E.H., Kitson J., and Seeger C. Role of RNA in enzymatic activity of the reverse transcriptase of hepatitis B viruses. J. Virol. 68 12 (1994) 8437-8442
52. Wang J.H., Lu S.N., Lee C.M., Lee J.F., and Chou Y.P. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 37 3 (2002) 366-369
53. Yaginuma K., Shirakata Y., Kobayashi M., and Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc. Natl. Acad. Sci. U. S. A. 84 9 (1987) 2678-2682
54. Ziermann R., and Ganem D. Homologous and heterologous complementation of HBV and WHV capsid and polymerase functions in RNA encapsidation. Virology 219 2 (1996) 350-356
55. Zhang Z., and Tavis J.E. The duck hepatitis B virus reverse transcriptase functions as a full-length monomer. J. Biol. Chem. 281 47 (2006) 35794-35801
56. Zhang X., Liu C., Gong Q., Zhang S., Zhang D., Lu Z., and Wang Y. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J. Gastroenterol. Hepatol. 18 12 (2003) 1353-1357